Innoviva, Inc.
Every calculator, already run for INVA
Open the full toolkit →You have the numbers on INVA. Get the argument.
A written report on which of these readings actually decide the outcome for Innoviva, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering INVAOwnership & short interest
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated…
INVA — frequently asked
Is INVA a buy right now?
Wall Street's consensus rating on Innoviva, Inc. is none across 4 analysts, with a mean price target of $35.50 (+73% vs. the current $20.51). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is INVA overvalued?
INVA trades at 3.3x trailing earnings, against a DCF fair value of $55 per share. The current price implies -6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Innoviva, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Innoviva, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full INVA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Innoviva, Inc., in minutes. 3 free reports included with every account — no credit card required.